iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Gufic Biosciences gains on DCGA nod for Thymosin Alpha-1

6 Apr 2022 , 11:14 AM

Immunocin α, an Immuno-modulator and a brand of Gufic Biosciences for the same drug, will significantly reduce the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe COVID-19. The medical armamentarium urgently needs many more tools to fight the COVID-19 pandemic, which is a leading cause of mortality and a strain on the social wellbeing and healthcare system all around the world, the press statement highlighted.

Immunocin α Phase 3 Study was a, multi-centric, randomized, placebo-controlled, double-blind study in hospitalized adult patients with laboratory-confirmed moderate-to-severe COVID-19. The primary objective of the study was to assess and compare the efficacy of Thymosin α-1 (Tα1) in combination with Standard of Care Treatment (SOC) versus placebo with SOC.

Gufic Biosciences is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

On a consolidated basis, the company reported a 36% jump in net profit to Rs 21 crore on a 3.3% rise in net sales to Rs 172 crore in Q3 FY22 over Q3 FY21.

Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.